United Therapeutics Total Assets 2006-2019 | UTHR

United Therapeutics total assets from 2006 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
United Therapeutics Annual Total Assets
(Millions of US $)
2018 $3,401
2017 $2,879
2016 $2,326
2015 $2,184
2014 $1,884
2013 $2,088
2012 $1,627
2011 $1,518
2010 $1,432
2009 $1,052
2008 $875
2007 $587
2006 $477
2005 $291
United Therapeutics Quarterly Total Assets
(Millions of US $)
Q3 2019 $4,000
Q2 2019 $3,899
Q1 2019 $3,727
Q4 2018 $3,401
Q3 2018 $3,412
Q2 2018 $3,245
Q1 2018 $3,020
Q4 2017 $2,879
Q3 2017 $2,936
Q2 2017 $2,692
Q1 2017 $2,561
Q4 2016 $2,326
Q3 2016 $2,269
Q2 2016 $2,202
Q1 2016 $2,192
Q4 2015 $2,184
Q3 2015 $2,159
Q2 2015 $1,737
Q1 2015 $1,895
Q4 2014 $1,884
Q3 2014 $2,072
Q2 2014 $1,953
Q1 2014 $2,115
Q4 2013 $2,088
Q3 2013 $1,928
Q2 2013 $1,778
Q1 2013 $1,697
Q4 2012 $1,627
Q3 2012 $1,647
Q2 2012 $1,556
Q1 2012 $1,561
Q4 2011 $1,518
Q3 2011 $1,667
Q2 2011 $1,579
Q1 2011 $1,485
Q4 2010 $1,432
Q3 2010 $1,283
Q2 2010 $1,188
Q1 2010 $1,127
Q4 2009 $1,052
Q3 2009 $1,005
Q2 2009 $952
Q1 2009 $903
Q4 2008 $875
Q3 2008 $767
Q2 2008 $680
Q1 2008 $638
Q4 2007 $587
Q3 2007 $513
Q2 2007 $472
Q1 2007 $436
Q4 2006 $477
Q3 2006 $298
Q2 2006 $325
Q1 2006 $305
Q4 2005 $291
Q3 2005 $257
Q2 2005 $234
Q1 2005 $217
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $4.131B $1.628B
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $66.320B 39.67
Takeda Pharmaceutical (TAK) Japan $62.530B 9.88
Astellas Pharma (ALPMY) Japan $32.752B 16.36
Eisai (ESALY) Japan $21.446B 41.35
Merck (MKGAF) Germany $16.524B 22.55
Grifols, S.A (GRFS) Spain $16.267B 21.32
Neurocrine Biosciences (NBIX) United States $9.792B 462.30
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Catalent (CTLT) United States $8.994B 36.59
Ionis Pharmaceuticals (IONS) United States $8.645B 17.51
Jazz Pharmaceuticals (JAZZ) Ireland $8.576B 10.95
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
IPSEN SA ADR (IPSEY) France $7.592B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.990B 0.00
Orion OYJ (ORINY) Finland $5.849B 30.12
Hypermarcas (HYPMY) Brazil $5.621B 20.20
Arrowhead Pharmaceuticals (ARWR) United States $5.466B 82.77
STADA ARZNEIMI (STDAF) Germany $5.375B 0.00
Nektar Therapeutics (NKTR) United States $4.205B 0.00
Evotec AG (EVTCY) Germany $4.021B 64.99
FibroGen (FGEN) United States $3.890B 114.33
Sage Therapeutics (SAGE) United States $3.839B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.293B 12.12
PTC Therapeutics (PTCT) United States $3.234B 0.00
Zogenix (ZGNX) United States $2.504B 0.00
ChemoCentryx (CCXI) United States $2.376B 0.00
Xencor (XNCR) United States $2.143B 65.15
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.123B 0.00
Heron Therapeutics (HRTX) United States $2.063B 0.00
Tilray (TLRY) Canada $2.053B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.993B 63.55
Pacira Pharmaceuticals (PCRX) United States $1.836B 54.32
USANA Health Sciences (USNA) United States $1.756B 18.74
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.600B 10.92
CLINIGEN GP (CLIGF) United Kingdom $1.506B 0.00
Corcept Therapeutics (CORT) United States $1.502B 18.25
Theravance Biopharma (TBPH) Cayman Islands $1.445B 0.00
Endo (ENDP) Ireland $1.401B 2.58
Karyopharm Therapeutics (KPTI) United States $1.182B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.156B 26.39
Portola Pharmaceuticals (PTLA) United States $1.151B 0.00
Aerie Pharmaceuticals (AERI) United States $1.117B 0.00
Dermira (DERM) United States $1.044B 0.00
Akebia Therapeutics (AKBA) United States $0.925B 0.00
Radius Health (RDUS) United States $0.912B 0.00
Collegium Pharmaceutical (COLL) United States $0.802B 0.00
ImmunoGen (IMGN) United States $0.723B 0.00
Flexion Therapeutics (FLXN) United States $0.681B 0.00
TherapeuticsMD (TXMD) United States $0.645B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.603B 0.00
Molecular Templates (MTEM) United States $0.516B 0.00
Organogenesis Holdings (ORGO) United States $0.503B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.501B 0.00
Translate Bio (TBIO) United States $0.501B 0.00
DURECT (DRRX) United States $0.489B 0.00
Ardelyx (ARDX) United States $0.472B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.459B 0.00
Siga Technologies (SIGA) United States $0.443B 10.11
Catalyst Pharmaceuticals (CPRX) United States $0.441B 53.50
BioCryst Pharmaceuticals (BCRX) United States $0.420B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.419B 18.05
Aptorum Group (APM) Hong Kong, SAR China $0.408B 0.00
Lannett Co Inc (LCI) United States $0.405B 4.72
Innate Pharma SA (IPHYF) France $0.403B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.372B 0.00
Calithera Biosciences (CALA) United States $0.372B 0.00
Recro Pharma (REPH) United States $0.370B 0.00
OptiNose (OPTN) United States $0.367B 0.00
Harpoon Therapeutics (HARP) United States $0.363B 0.00
Indivior (INVVY) United States $0.338B 1.22
Rafael Holdings (RFL) United States $0.320B 0.00
KalVista Pharmaceuticals (KALV) United States $0.317B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.288B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.287B 0.00
Jounce Therapeutics (JNCE) United States $0.250B 3.35
Concert Pharmaceuticals (CNCE) United States $0.250B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.239B 0.00
MEI Pharma (MEIP) United States $0.239B 0.00
Concordia (CXRXF) Canada $0.225B 0.00
Ocular Therapeutix (OCUL) United States $0.221B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.215B 0.00
IMV INC (IMV) Canada $0.205B 0.00
Nature's Sunshine Products (NATR) United States $0.187B 32.20
Taiwan Liposome (TLC) Taiwan $0.170B 0.00
Xeris Pharmaceuticals (XERS) United States $0.169B 0.00
CannTrust Holdings (CTST) Canada $0.166B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.158B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.149B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.137B 0.00
Redhill Biopharma (RDHL) Israel $0.133B 0.00
PolarityTE (PTE) United States $0.119B 0.00
Otonomy (OTIC) United States $0.110B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.109B 0.00
CV Sciences (CVSI) United States $0.108B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.105B 0.00
Aquestive Therapeutics (AQST) United States $0.104B 0.00
Champions Oncology (CSBR) United States $0.099B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.098B 0.00
Aclaris Therapeutics (ACRS) United States $0.082B 0.00
MediWound (MDWD) Israel $0.082B 0.00
CTI BioPharma (CTIC) United States $0.080B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.079B 23.59
Neos Therapeutics (NEOS) United States $0.079B 0.00
Nivalis Therapeutics (ALPN) United States $0.071B 0.00
Infinity Pharmaceuticals (INFI) United States $0.068B 0.00
AgeX Therapeutics (AGE) United States $0.067B 0.00
Natural Alternatives (NAII) United States $0.065B 16.14
Entasis Therapeutics Holdings (ETTX) United States $0.063B 0.00
SCYNEXIS (SCYX) United States $0.063B 0.00
Iterum Therapeutics (ITRM) Ireland $0.062B 0.00
RENEURON GP (RNUGF) United Kingdom $0.061B 0.00
Onconova Therapeutics (ONTX) United States $0.060B 0.00
IsoRay (ISR) United States $0.056B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.055B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.049B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.048B 0.00
Forward Pharma (FWP) Denmark $0.044B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.044B 0.00
ElectroCore (ECOR) United States $0.041B 0.00
Jaguar Animal Health (JAGX) United States $0.041B 0.00
Mannatechorporated (MTEX) United States $0.039B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.031B 0.00
India Globalization Capital (IGC) United States $0.030B 0.00
Biomerica (BMRA) United States $0.029B 0.00
PharmAthene (ALT) United States $0.028B 0.00
Regulus Therapeutics (RGLS) United States $0.026B 0.00
China SXT Pharmaceuticals (SXTC) China $0.025B 0.00
Bio-Path Holdings (BPTH) United States $0.022B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Cardiome Pharma (CORV) Canada $0.019B 0.00
VAXART, INC (VXRT) United States $0.019B 0.00
Shineco (TYHT) China $0.018B 0.00
Novan (NOVN) United States $0.017B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.017B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.016B 0.00
Cyanotech (CYAN) United States $0.015B 0.00
Lipocine (LPCN) United States $0.014B 0.00
Flex Pharma (SLRX) United States $0.014B 0.00
Heat Biologics (HTBX) United States $0.012B 0.00
Vical (BBI) United States $0.012B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.010B 0.00
HANCOCK JAFFE (HJLI) United States $0.010B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.006B 0.00
Hemispherx BioPharma (AIM) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Can-Fite Biopharma (CANF) Israel $0.004B 0.00
Midatech Pharma (MTP) United Kingdom $0.003B 0.00